Variants of TACE pro-domain as TNF-A inhibitor and their medical use

    公开(公告)号:US10933122B2

    公开(公告)日:2021-03-02

    申请号:US16521622

    申请日:2019-07-25

    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

    Variants of TACE pro-domain as TNF-A inhibitor and their medical use

    公开(公告)号:US10426821B2

    公开(公告)日:2019-10-01

    申请号:US15636683

    申请日:2017-06-29

    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

    VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE
    6.
    发明申请
    VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE 有权
    作为TNF-A抑制剂的TACE类型的变体及其医学用途

    公开(公告)号:US20150132281A1

    公开(公告)日:2015-05-14

    申请号:US14398754

    申请日:2013-05-09

    CPC classification number: A61K38/4886 C12N9/6489 C12Y304/24086 Y02A50/473

    Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

    Abstract translation: 公开了一种治疗炎性疾病的方法。 该方法包括向受试者施用治疗有效量的包含TNF-α转换酶(TACE)的前域的多肽,所述多肽缺乏所述TACE的催化结构域,所述多肽在所选择的位点包含修饰 来自由R58,R56和K57组成的组,其使所述多肽对弗林蛋白酶降解具有抗性,所述多肽能够下调TACE的活性,从而治疗炎性疾病。

Patent Agency Ranking